No evidence – NAFDAC speaks on low-quality paracetamol in Nigerian markets

The National Agency for Food and Drug Administration (NAFDAC) has responded to allegations of the proliferation of substandard paracetamol in Nigeria’s pharmaceutical market.

In a statement released on Monday, Sayo Akintola, NAFDAC’s media consultant, clarified that there is no evidence supporting the claim of the circulation of inferior-quality paracetamol in the country.

The agency, in affirming its commitment to ensuring the health of the nation, reassured the public of its continuous vigilance. Akintola stated, “We have received a copy of the publication of the research findings on the subject, and we wish to state categorically that the report is misleading and the science is questionable.”

He further explained that NAFDAC conducts an annual post-marketing survey of medicines to verify the maintenance of quality and safety. In cases where deviations are identified, such as substandard or falsified regulated products, NAFDAC promptly issues public alerts or recalls.

NAFDAC emphasized its dedication to ensuring the well-being of the nation, reassuring the public that the agency remains highly vigilant in safeguarding the health of the country.